Steward Partners Investment Advisory’s Catalyst Pharmaceutical CPRX Stock Holding History

Steward Partners Investment Advisory’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.2K	Hold	734	–	–	﹤0.01%	3275
2025 Q4	$17.1K	Hold	734	–	–	﹤0.01%	3198
2025 Q3	$14.5K	Hold	734	–	–	﹤0.01%	3237
2025 Q2	$15.9K	Sell	734 -43,021	-98%	-$1.02M	﹤0.01%	3008
2025 Q1	$1.06M	Buy	43,755 +42,482	+3,337%	+$957K	0.01%	895
2024 Q4	$26.6K	Buy	+1,273	New	+$27.3K	﹤0.01%	2644
2024 Q1	–	Sell	-600	Closed	-$10.1K	–	3592
2023 Q4	$10.1K	Hold	600	–	–	﹤0.01%	2709
2023 Q3	$7.01K	Buy	600 +100	+20%	+$1.34K	﹤0.01%	2705
2023 Q2	$6.72K	Buy	500 +300	+150%	+$4.32K	﹤0.01%	2695
2023 Q1	$3.32K	Buy	200 +120	+150%	+$1.98K	﹤0.01%	2911
2022 Q4	$1.49K	Hold	80	–	–	﹤0.01%	3077
2022 Q3	$1K	Buy	+80	New	+$948	﹤0.01%	3109
2021 Q2	–	Sell	-2,600	Closed	-$12K	–	7147
2021 Q1	$12K	Buy	+2,600	New	+$10.3K	﹤0.01%	2704
2020 Q1	–	Sell	-2,500	Closed	-$9K	–	2521
2019 Q4	$9K	Sell	2,500 -2,000	-44%	-$9.35K	﹤0.01%	2042
2019 Q3	$23K	Buy	4,500 +2,000	+80%	+$10.7K	﹤0.01%	1675
2019 Q2	$9K	Buy	+2,500	New	+$10.8K	﹤0.01%	2012
2018 Q4	–	Sell	-2,500	Closed	-$9K	–	1020
2018 Q3	$9K	Hold	2,500	–	–	﹤0.01%	1910
2018 Q2	$8K	Buy	+2,500	New	+$7.58K	﹤0.01%	1807

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Steward Partners Investment Advisory's CPRX Position: Q1 2026 in Review

Steward Partners Investment Advisory held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 734 shares worth $18.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

Steward Partners Investment Advisory first reported a position in CPRX in Q2 2018 and has held it in 18 quarters since. The position peaked at $1.06M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Steward Partners Investment Advisory held 734 shares of Catalyst Pharmaceutical worth $18.2K as of Q1 2026.
Steward Partners Investment Advisory left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3275 holding.
Steward Partners Investment Advisory first reported a position in Catalyst Pharmaceutical in Q2 2018 and has held it in 18 quarters since.
Steward Partners Investment Advisory's Catalyst Pharmaceutical position peaked at $1.06M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.